+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Eosinophilic Esophagitis - Pipeline Review, H2 2019

  • ID: 4894203
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 115 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Adare Pharmaceuticals Inc
  • Banner Life Sciences LLC
  • Celgene Corp
  • Dr. Falk Pharma GmbH
  • GlaxoSmithKline Plc
  • Kyowa Kirin Co Ltd
  • MORE
Eosinophilic Esophagitis - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Eosinophilic Esophagitis - Pipeline Review, H2 2019, provides an overview of the Eosinophilic Esophagitis (Gastrointestinal) pipeline landscape.

Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting, coughing, heartburn and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity and alcohol and cigarette use. Treatment includes antiviral, antifungal and pain relievers.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Eosinophilic Esophagitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Eosinophilic Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 5 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Eosinophilic Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Eosinophilic Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Eosinophilic Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Eosinophilic Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Adare Pharmaceuticals Inc
  • Banner Life Sciences LLC
  • Celgene Corp
  • Dr. Falk Pharma GmbH
  • GlaxoSmithKline Plc
  • Kyowa Kirin Co Ltd
  • MORE
Introduction
Report Coverage
Eosinophilic Esophagitis - Overview
Eosinophilic Esophagitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Eosinophilic Esophagitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Eosinophilic Esophagitis - Companies Involved in Therapeutics Development
Adare Pharmaceuticals Inc
Allakos Inc
Banner Life Sciences LLC
Calypso Biotech SA
Celgene Corp
DBV Technologies SA
Dr. Falk Pharma GmbH
EsoCap AG
GlaxoSmithKline Plc
Humanigen Inc
Kyowa Kirin Co Ltd
Morphic Holding Inc
Quorum Innovations LLC
RAPT Therapeutics Inc
Regeneron Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Eosinophilic Esophagitis - Drug Profiles
AK-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benralizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
budesonide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
budesonide ODT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CALY-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cendakimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dupilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
esomeprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluticasone propionate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluticasone propionate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HGEN-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mepolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mometasone furoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MR Beta7-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MR Beta7-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Qi-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RNAi Gene Therapy for Asthma and Eosinophilic Esophagitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPT-193 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Viaskin Milk - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Eosinophilic Esophagitis - Dormant Projects
Eosinophilic Esophagitis - Product Development Milestones
Featured News & Press Releases
Oct 28, 2019: First-Ever U.S. pivotal Phase 3 clinical study in eosinophilic esophagitis (EoE) completes: Takeda's investigational therapy meets co-primary & key secondary efficacy endpoints
Aug 28, 2019: Fasenra granted US Orphan Drug Designation for eosinophilic oesophagitis
Jul 23, 2019: EsoCap receives orphan drug designation from the US food & drug administration for ESO-101
Mar 11, 2019: Adare Pharmaceuticals announces achievement of the primary end-point in phase IIb study (FLUTE) for APT-1011 in patients with eosinophilic esophagitis
Oct 16, 2017: Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
Feb 03, 2017: DBV Technologies Announces Completion of Enrollment of Phase IIA Study of Viaskin Milk for the Treatment of Pediatric Eosinophilic Esophagitis
Oct 13, 2016: Celgene to Present New Data on RPC4046 at UEGW and ACG Congresses
Sep 21, 2016: DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cows Milk Protein Allergy
Jun 13, 2016: Shire Receives FDA Breakthrough Therapy Designation for Investigational Product SHP621 for Rare Gastrointestinal Conditions
Nov 12, 2015: DBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic Esophagitis
Jul 08, 2015: IND Acceptance from FDA for a proof-of-concept trial using Viaskin® Milk in Milk-Induced Eosinophilic Esophagitis in Children
Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis
Sep 25, 2014: Meritage Pharma Announces Positive Results of Oral Budesonide Suspension for Treatment of Eosinophilic Esophagitis in Adolescent and Adult Patients
Jul 21, 2014: High-dose fluticasone effective against eosinophilic esophagitis
May 13, 2014: DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Eosinophilic Esophagitis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Eosinophilic Esophagitis - Pipeline by Adare Pharmaceuticals Inc, H2 2019
Eosinophilic Esophagitis - Pipeline by Allakos Inc, H2 2019
Eosinophilic Esophagitis - Pipeline by Banner Life Sciences LLC, H2 2019
Eosinophilic Esophagitis - Pipeline by Calypso Biotech SA, H2 2019
Eosinophilic Esophagitis - Pipeline by Celgene Corp, H2 2019
Eosinophilic Esophagitis - Pipeline by DBV Technologies SA, H2 2019
Eosinophilic Esophagitis - Pipeline by Dr. Falk Pharma GmbH, H2 2019
Eosinophilic Esophagitis - Pipeline by EsoCap AG, H2 2019
Eosinophilic Esophagitis - Pipeline by GlaxoSmithKline Plc, H2 2019
Eosinophilic Esophagitis - Pipeline by Humanigen Inc, H2 2019
Eosinophilic Esophagitis - Pipeline by Kyowa Kirin Co Ltd, H2 2019
Eosinophilic Esophagitis - Pipeline by Morphic Holding Inc, H2 2019
Eosinophilic Esophagitis - Pipeline by Quorum Innovations LLC, H2 2019
Eosinophilic Esophagitis - Pipeline by RAPT Therapeutics Inc, H2 2019
Eosinophilic Esophagitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
Eosinophilic Esophagitis - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Eosinophilic Esophagitis - Dormant Projects, H2 2019

List of Figures
Number of Products under Development for Eosinophilic Esophagitis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Adare Pharmaceuticals Inc
  • Allakos Inc
  • Banner Life Sciences LLC
  • Calypso Biotech SA
  • Celgene Corp
  • DBV Technologies SA
  • Dr. Falk Pharma GmbH
  • EsoCap AG
  • GlaxoSmithKline Plc
  • Humanigen Inc
  • Kyowa Kirin Co Ltd
  • Morphic Holding Inc
  • Quorum Innovations LLC
  • RAPT Therapeutics Inc
  • Regeneron Pharmaceuticals Inc
  • Takeda Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll